Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MIRM Stock Forecast 2026-2027
$119.04
Current Price
$7.26B
Market Cap
Buy 14
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to MIRM Price Targets
+55.4%
To High Target of $185.00
+21.8%
To Median Target of $145.00
+5.0%
To Low Target of $125.00
MIRM Price Momentum
-7.2%
1 Week Change
+19.8%
1 Month Change
+123.4%
1 Year Change
+50.7%
Year-to-Date Change
-8.4%
From 52W High of $130.00
+136.9%
From 52W Low of $50.25
📊 TOP ANALYST CALLS
Did MIRM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Mirum is one of their latest high-conviction picks.
Latest MIRM Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, MIRM has a bullish consensus with a median price target of $145.00 (ranging from $125.00 to $185.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $119.04, the median forecast implies a 21.8% upside. This outlook is supported by 14 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Jessica Fye at JP Morgan, suggesting a 5.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MIRM Analyst Ratings
14
Buy
0
Hold
0
Sell
MIRM Price Target Range
Low
$125.00
Average
$145.00
High
$185.00
Current: $119.04
Latest MIRM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MIRM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 7, 2026 | RBC Capital | Lisa Walter | Outperform | Maintains | $148.00 |
| Jul 2, 2026 | JP Morgan | Jessica Fye | Overweight | Maintains | $125.00 |
| Jun 15, 2026 | Citizens | Market Outperform | Maintains | $N/A | |
| Jun 11, 2026 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Jun 2, 2026 | Citigroup | Buy | Initiates | $N/A | |
| May 19, 2026 | Wolfe Research | Outperform | Initiates | $N/A | |
| May 7, 2026 | TD Cowen | Buy | Maintains | $N/A | |
| May 7, 2026 | RBC Capital | Outperform | Maintains | $N/A | |
| May 7, 2026 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| May 7, 2026 | Baird | Outperform | Maintains | $N/A | |
| May 5, 2026 | Morgan Stanley | Overweight | Maintains | $N/A | |
| May 4, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Apr 29, 2026 | Stifel | Buy | Maintains | $N/A | |
| Apr 28, 2026 | Baird | Outperform | Maintains | $N/A | |
| Apr 27, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Apr 21, 2026 | Citizens | Market Outperform | Reiterates | $N/A | |
| Mar 27, 2026 | TD Cowen | Buy | Maintains | $N/A | |
| Mar 23, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 4, 2026 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| Feb 26, 2026 | Leerink Partners | Outperform | Maintains | $N/A |
Mirum Pharmaceuticals Inc. (MIRM) Competitors
The following stocks are similar to Mirum based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Mirum Pharmaceuticals Inc. (MIRM) Financial Data
Mirum Pharmaceuticals Inc. has a market capitalization of $7.26B with a P/E ratio of -253.2x. The company generates $569.61M in trailing twelve-month revenue with a -140.2% profit margin.
Revenue growth is +43.3% quarter-over-quarter, while maintaining an operating margin of -39.5% and return on equity of -335.8%.
Valuation Metrics
Market Cap
$7.26B
Enterprise Value
$7.39B
P/E Ratio
-253.2x
PEG Ratio
-0.1x
Price/Sales
13.1x
Growth & Margins
Revenue Growth (YoY)
+43.3%
Gross Margin
+82.0%
Operating Margin
-39.5%
Net Margin
-140.2%
EPS Growth
+43.3%
Financial Health
Cash/Price Ratio
+5.3%
Current Ratio
2.1x
Debt/Equity
133.5x
ROE
-335.8%
ROA
-5.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Mirum Pharmaceuticals Inc. (MIRM) Business Model
About Mirum Pharmaceuticals Inc.
What They Do
Develops therapies for rare diseases.
Business Model
Mirum Pharmaceuticals focuses on developing and commercializing innovative therapies specifically for rare diseases, particularly liver diseases. The company generates revenue through the successful development and commercialization of its therapies, which address significant unmet medical needs in niche patient populations.
Additional Information
Mirum is particularly known for its work on Alagille syndrome and is committed to advancing research and facilitating regulatory approval processes to ensure global access to its treatments. The company plays a vital role in improving the quality of life for patients with chronic liver conditions and is considered a key player in the biopharmaceutical industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
418
CEO
Mr. Christopher Peetz
Country
United States
IPO Year
2019
Website
www.mirumpharma.comMirum Pharmaceuticals Inc. (MIRM) Latest News & Analysis
Latest News
Quick Summary
Mirum Pharmaceuticals aims to lead in liver disease, raising 2026 sales guidance to $660–$680M, driven by LIVMARLI. Acquisitions delay cash flow positivity to 2028, but promising pipeline exists.
Why It Matters
Mirum's strong revenue growth and revised sales guidance indicate potential for significant returns. The diversified pipeline suggests future catalysts, despite delayed cash flow, enhancing long-term investment appeal.
Source: Seeking Alpha
Market Sentiment:
Positive
Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?
15 days ago
Quick Summary
Mirum Pharmaceuticals (MIRM) shares rose with above-average trading volume, but recent earnings estimate revisions may not lead to immediate further price increases.
Why It Matters
Mirum Pharmaceuticals' share surge indicates strong investor interest, but the mixed outlook on earnings revisions suggests potential volatility ahead, impacting investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Biotech ETF Index Surges 10% After Rebalance
19 days ago
Quick Summary
The ALPS Medical Breakthroughs ETF (SBIO) saw its underlying biotech index rise by 10.01% within six trading days post its June 18 semi-annual rebalance.
Why It Matters
The 10% gain in the biotech index after the rebalance signals potential growth in the sector, which could attract more investment and boost SBIO's performance.
Source: ETF Trends
Market Sentiment:
Positive
Quick Summary
Mirum and Incyte's zilurgisertib reduced new bone lesions in fibrodysplasia ossificans progressiva (FOP). The FDA has initiated a Priority Review of its NDA, with a decision expected by Sept. 26, 2026.
Why It Matters
Positive clinical results and FDA Priority Review for zilurgisertib could lead to market approval, potentially boosting Mirum and Incyte's stock prices and attracting investor interest in rare disease therapies.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Mirum and Incyte's zilurgisertib reduced new bone lesions in FOP. The FDA has initiated a Priority Review of the NDA, with a decision expected by September 26, 2026.
Why It Matters
Positive clinical results for zilurgisertib in treating FOP may boost Mirum and Incyte's stock value, while FDA priority review could accelerate market entry and revenue potential.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Mirum Pharmaceuticals and Incyte reported positive Phase 2 results from the PROGRESS study for Zilurgisertib, a treatment for Fibrodysplasia Ossificans Progressiva (FOP).
Why It Matters
Positive Phase 2 results for Zilurgisertib could indicate a promising treatment for FOP, potentially boosting Mirum Pharmaceuticals and Incyte's stock value and attracting investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About MIRM Stock
What is Mirum Pharmaceuticals Inc.'s (MIRM) stock forecast for 2027?
Based on our analysis of 6 Wall Street analysts, Mirum Pharmaceuticals Inc. (MIRM) has a median price target of $145.00. The highest price target is $185.00 and the lowest is $125.00.
Is MIRM stock a good investment in 2027?
According to current analyst ratings, MIRM has 14 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $119.04. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MIRM stock?
Wall Street analysts predict MIRM stock could reach $145.00 in the next 12 months. This represents a 21.8% increase from the current price of $119.04. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Mirum Pharmaceuticals Inc.'s business model?
Mirum Pharmaceuticals focuses on developing and commercializing innovative therapies specifically for rare diseases, particularly liver diseases. The company generates revenue through the successful development and commercialization of its therapies, which address significant unmet medical needs in niche patient populations.
What is the highest forecasted price for MIRM Mirum Pharmaceuticals Inc.?
The highest price target for MIRM is $185.00 from at , which represents a 55.4% increase from the current price of $119.04.
What is the lowest forecasted price for MIRM Mirum Pharmaceuticals Inc.?
The lowest price target for MIRM is $125.00 from Jessica Fye at JP Morgan, which represents a 5.0% increase from the current price of $119.04.
What is the overall MIRM consensus from analysts for Mirum Pharmaceuticals Inc.?
The overall analyst consensus for MIRM is bullish. Out of 6 Wall Street analysts, 14 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $145.00.
How accurate are MIRM stock price projections?
Stock price projections, including those for Mirum Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2026 12:21 PM UTC